Todd K. Fox
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies.
Journal: The Journal of rheumatology
Published: February 26, 2021
Secukinumab's effect on structural damage progression in psoriatic arthritis: longitudinal mixture modelling of FUTURE-1 and FUTURE-5.
Journal: Clinical and experimental rheumatology
Published: April 01, 2020
Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison.
Journal: Arthritis research & therapy
Published: November 29, 2018
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
Journal: Arthritis research & therapy
Published: November 12, 2018
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.
Journal: Annals of the rheumatic diseases
Published: August 13, 2018
Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.
Journal: Arthritis research & therapy
Published: January 02, 2018
No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis.
Journal: The British journal of dermatology
Published: October 10, 2017
Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 25, 2017
Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results.
Journal: Journal of drugs in dermatology : JDD
Published: August 16, 2017
Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials.
Journal: Advances in therapy
Published: June 08, 2017
Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.
Journal: The British journal of dermatology
Published: May 31, 2017
Last Updated: 09/26/2026